Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Marine Gross‐Goupil(Centre Hospitalier Universitaire de Bordeaux), Tae‐Geon Kwon(Kyungpook National University), Masatoshi Eto(Kyushu University), Dingwei Ye(Fudan University Shanghai Cancer Center), Hideaki Miyake(Hamamatsu University), S.I. Seo(Sungkyunkwan University), S.-S. Byun(Seoul National University Bundang Hospital), Jia-Lin Lee(Asan Medical Center), Viraj A. Master(Emory University), Jie Jin(Peking University First Hospital), R. DeBenedetto(JT Pharmaceuticals (United States)), R. Linke(JT Pharmaceuticals (United States)), Michelle Casey(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Mariajosé Lechuga(Pfizer (Italy)), Olga Valota(Pfizer (Italy)), Enrique Grande(MD Anderson Cancer Center Madrid), David I. Quinn(USC Norris Comprehensive Cancer Center)
Cited by 256Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis